Toshihiko Doi, MD, PhD
Pembrolizumab (Keytruda) induced an overall response rate (ORR) of 30% (95% CI, 13%-53%) in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, according to findings from the phase Ib KEYNOTE-028 trial published in the Journal of Clinical Oncology.
Three patients experienced serious treatment-related AEs: grade 2 pemphigoid, grade 3 decreased appetite, and grade 3 liver disorder in 1 patient each. All resolved with either discontinuation (liver disorder) or no action taken (pemphigoid and decreased appetite). There were no deaths due to treatment-related AEs.
Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma [published online November 8, 2017]. J Clin Oncol doi: 10.1200/JCO.2017.74.9846.
... to read the full story